Broeryan5635
related proteins in both livers of the copper-loaded and copper-stimulated BRL-3A cell lines.
GDD had apparent therapeutic effects on the hepatic injury of copper-loaded rats and copper-stimulated BRL-3A cells. Its mechanism is related to its regulatory effect on the Wnt/β-catenin pathway rectification and oxidative stress antagonism.
GDD had apparent therapeutic effects on the hepatic injury of copper-loaded rats and copper-stimulated BRL-3A cells. Its mechanism is related to its regulatory effect on the Wnt/β-catenin pathway rectification and oxidative stress antagonism.
Geniposide (GE) is the main component in gardenia fruit. This study aimed to investigate the protective effects and potential mechanisms of GE on dextran sulfate sodium (DSS)-induced colitis in mice and lipopolysaccharide (LPS)-induced RAW 264.7 cells.
The in vivo acute colitis experimental model was established by administering drinking water containing 3% DSS to the mice for 7 days. GE was administered to the mice via oral gavage at 20 and 40 mg/kg for 7 days. Colon length, colon myeloperoxidase (MPO) level, serum and colon malondialdehyde (MDA) levels, and superoxide dismutase (SOD) activity were determined, and histological evaluation was performed. The levels of interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-α (TNF-α) in the serum and colon were detected. The expression of proteins of the nuclear factor E2 related factor 2 (Nrf-2)/HO-1/ NF-κB pathway in the colon was detected. The in vitro model of LPS-induced RAW 264.7 cells to simulate enteritis model. Cell viability, IL-6, IL-1β, and TNF-αe findings demonstrated that GE ameliorated inflammation and oxidative stress in experimental colitis via modulation of the Nrf-2/HO-1/NF-κB pathway. selleck Thus, GE could serve as a potential therapeutic agent for the treatment of ulcerative colitis (UC).
Cardiovascular diseases are currently prevalent in cardiology and vascular surgery in the hospital. The purpose of this study based on text mining and microarray data analysis was designed to find some existing drugs target to gene and expand the potential new drug indications.
Firstly, we used text mining ("Atherosclerosis") and microarray data analysis (GSE28829) to obtain a common set of genes. Secondly, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis performed to these genes, as well as protein-protein interaction (PPI) network. Then, the significant genes clustered in the PPI network were chose to execute gene-drug interaction analysis for potential drug discovery.
We got 1,788 text mining genes (TMGs) and 275 differentially expressed genes (DEGs) through text mining and data analysis, respectively. Ninety-three genes were duplicated between TMGs and DEGs, in which 89 genes were up-regulated genes and four genes were down regulated. Twenty-three genes clustered in the significant gene module. Lastly, the eight out of 23 genes can target 20 existing drugs.
The findings of these eight genes (VCAM1, CSF1R, C5AR1, CXCR4, CD86, CCR1, ITGB2, TLR8), which were associated with inflammatory response, target to 20 existing drugs may expand drug indications to atherosclerosis-related disease.
The findings of these eight genes (VCAM1, CSF1R, C5AR1, CXCR4, CD86, CCR1, ITGB2, TLR8), which were associated with inflammatory response, target to 20 existing drugs may expand drug indications to atherosclerosis-related disease.
To establish and validate a nomogram to predict liver metastasis in patients with small-cell lung cancer (SCLC).
Information on patients diagnosed with SCLC between 2010 and 2015 was retrospectively retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Risk factors for liver metastasis were identified by logistic regression analyses to construct a nomogram. The predictive accuracy was evaluated by concordance indexes (c-index) and calibration plots, and the comparison of discrimination between the nomogram and other routine staging systems was achieved with the area under receiver operating characteristic curve (AUC) analysis. Decision curve analysis (DCA) was performed to measure the clinical performance of the nomogram.
A total of 12,957 patients met our inclusion criteria and were randomly assigned to training (n=6,479) and validation (n=6,478) sets. The nomogram which was established based on independent clinicopathological factors had poor accuracy, and after other distant metastatic sites were added into the predictive model, the new nomogram displayed better discrimination power, with c-indexes of 0.703 in the training set and 0.712 in the validation set. Both internal and external calibration plots approached 45 degrees. The AUCs and net benefit of the predictive model were both higher than those of routine staging systems.
The validated nomogram might be a practical tool for clinicians to quantify the risk of liver metastasis in patients with SCLC and improve cancer management.
The validated nomogram might be a practical tool for clinicians to quantify the risk of liver metastasis in patients with SCLC and improve cancer management.
More than half of cancer patients affected by cancer experience pain of moderate-tosevere intensity. Therefore, facilitating appropriate and safe administration of analgesics is crucial to the comprehensive management of cancer patients. In this article, we assessed medication adherence, pain relief, drug related problems (DRPs) and analgesics adverse events (AEs) in cancer pain patients based on a model of clinical pharmacy services.
In this prospective, single-arm intervention study, cancer pain patients admitted to our institution were eligible. According to different adherence, heterogeneity of pain, and individual treatment strategy, clinical pharmacists (CPs) provided comprehensive pain assessment and medication education for patients, as well as provided consultation and recommendation for physicians. CPs' pharmacy services were assessed through medication adherence, numbers of DRPs, acceptance of recommendation, pain intensity (PI), daily interference and AEs.
A total of 42 patients were enrolled between November, 2018 and November, 2019.